Smoking Cessation and Nicotine Addiction Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), | Key Companies – Achieve Life Sciences, NFL Biosciences SAS

DelveInsight Business Research LLP

DelveInsight’s “Smoking Cessation and Nicotine Addiction- Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the smoking cessation and nicotine addiction, historical and forecasted epidemiology as well as the smoking cessation and nicotine addiction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Smoking Cessation and Nicotine Addiction Overview

Nicotine/tobacco dependence is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated tobacco use and that typically include a strong desire to use tobacco, difficulties in controlling its use, persistence in tobacco use despite harmful consequences, a higher priority given to tobacco use than other activities and obligations, increased tolerance and sometimes a physical withdrawal state.

Repeated exposure to nicotine develops neuroadaptation of the receptors, resulting in tolerance to many of the effects of nicotine. Withdrawal symptoms appear on stoppage of tobacco use, characterized by irritability, anxiety, increased eating, dysphoria, and hedonic dysregulation, among others. Smoking is also reinforced by conditioning.

Smoking Cessation and Nicotine Addiction Epidemiology Insights

• In 2022, the market size of smoking cessation and nicotine addiction was highest in the US among the 7MM, accounting for approximately USD 1,470 million, and lowest in Germany with USD 46 million which is further expected to increase by 2032.

• Gender-specific prevalent cases of tobacco use were higher in males (around 82,660 thousand cases) as compared to females (around 54,350 thousand) in 2022 in the 7MM.

• According to DelveInsight estimates, EU4 and the UK accounted for approximately 64,670 thousand cases, which was the highest prevalent cases of tobacco use, followed by the US with around  51,500 thousand cases, and Japan with around 20,840 thousand cases in 2022. These cases are expected to decrease in the US, EU4 and the UK, and Japan by 2032

• Among the EU4 and the UK, Germany had the highest prevalent cases of tobacco use (approximately 18,350 thousand cases), followed by France (approximately 16,410 thousand cases) in 2022. On the other hand, the UK (9,000 thousand cases) had the lowest prevalent cases of tobacco use in EU4 and the UK countries and the 7MM.

• Tobacco use has been identified as male-dominant; in our analysis, the number of males suffering was higher than females. In 2022, 60% of prevalent cases tobacco use of was of males, while 40% of cases were of females in the 7MM.

Click here to learn more about the Smoking Cessation and Nicotine Addiction Market Landscape

The Report Covers the Smoking Cessation and Nicotine Addiction Epidemiology Segmented by:

• Smoking Cessation and Nicotine Addiction prevalent cases 

• Smoking Cessation and Nicotine Addiction diagnosed cases 

• Smoking Cessation and Nicotine Addiction treatment cases 

• Smoking Cessation and Nicotine Addiction incident cases 

Smoking Cessation and Nicotine Addiction Market Outlook 

There are effective treatments that support tobacco cessation, including both behavioral therapies and FDA-approved medications. Several distinct products and services are available today for smoking cessation, alongside smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapies (NRTs) in the form of transdermal patches, gums, nasal sprays, oral inhalers, and lozenges. The US FDA has approved two smoking cessation products that do not contain nicotine. They are CHANTIX (varenicline tartrate), and ZYBAN (bupropion hydrochloride). Both products are available in tablet form and by prescription only. In the past years, the generic of both the approved drug has entered the market. Both are widely available in the US and the European market. In Japan, varenicline (CHAMPIX), NRT, and some off-label therapies are used for smoking cessation. Bupropion-SR is not licensed in Japan for smoking cessation.

 Key Companies Working in the Smoking Cessation and Nicotine Addiction Market

• Achieve Life Sciences

• NFL Biosciences SAS

• Embera NeuroTherapeutics, Inc

• Axsome Therapeutics

• Currax Pharmaceuticals LLC

• Omeros Corporation

• Promentis Pharmaceuticals

• Otsuka Pharmaceutical

And many others 

Smoking Cessation and Nicotine Addiction Therapies Covered and Analyzed in the Report:

• Cytisine

• Liraglutide

• Varenicline

• Bupropion

• Chantix

• Zyban

• Bupropion

And many others 

Learn more about the Key Companies and Emerging Therapies in the Smoking Cessation and Nicotine Addiction Market

Table of Contents 

1. Key Insights 

2. Smoking Cessation and Nicotine Addiction  Introduction 

3. Executive Summary of Smoking Cessation and Nicotine Addiction   

4. Disease Background and Overview

5. Epidemiology and patient population

6. Smoking Cessation and Nicotine Addiction  Emerging Therapies

7. Smoking Cessation and Nicotine Addiction  Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Smoking Cessation and Nicotine Addiction  Market Outlook 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services